Posted by Michael Wonder on 16 Oct 2019
First Algenex CrisBio-based vaccine submitted to European Medicines Agency
15 October 2019 - Potential approval would validate the use of Algenex’ CrisBio technology for the manufacture of recombinant subunit vaccines.
Algenex today announces that one of its industry partners has submitted a dossier to the European Medicines Agency for a recombinant VLP vaccine produced using Algenex’ proprietary CrisBio technology.
The submission is targeting a European marketing authorization via the centralized approval system. This is the first vaccine produced using Algenex’ CrisBio technology to be submitted for regulatory approval.
